SpringWorks Therapeutics Developed Novel OGSIVEO™ for the Treatment of Desmoid Tumours
SpringWorks Therapeutics has developed OGSIVEO™ (nirogacestat) as the first and only treatment for adults with desmoid tumours.
OGSIVEO™ (nirogacestat) is an oral, selective, and has gained approval in the United States as small molecule gamma secretase inhibitor. It's specifically indicated for treating adult patients with advancing desmoid tumours necessitating systemic intervention.
The FDA approval of OGSIVEO relied on findings from the Phase 3 DeFi trial. OGSIVEO successfully achieved its primary goal of enhancing progression-free survival (PFS). The results showcased a remarkable 71 percent reduction in the risk of disease progression compared to the placebo, marking a statistically significant improvement.
Desmoid tumours are indeed locally aggressive and invasive, causing significant morbidity. When these tumours affect critical structures, they can pose life-threatening risks. Despite not spreading to other parts of the body, desmoid tumours often resist existing off-label systemic treatments, leading to recurrence rates as high as 77 percent even after surgical removal.
Desmoid tumours present substantial challenges in management due to their invasive tendencies and frequent recurrences, significantly impacting individuals' lives.
OGSIVEO represents a highly innovative therapy, backed by efficacy data showcasing both meaningful antitumor activity and a notable improvement in symptoms associated with desmoid tumours.
